Feedback
Settings

Settings

Goto Application

1,913 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(DXEJZRDJXRVUPN-XUTVFYLZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 192
1.WO/2025/240659ACTIVATABLE CONSTRUCTS, COMPOSITIONS AND METHODS
WO - 20.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/029426 Applicant CYTOMX THERAPEUTICS, INC. Inventor FOX, Ellaine Anne Mariano
Activatable constructs and methods of making and treating using the same, comprising a first antigen binding domain (AB1) having specific binding affinity for a first antigen, wherein the AB1 comprises a heavy chain variable domain 1 (HVD1) and a light chain variable domain 1 (LVD1), wherein the HVD1 is covalently coupled directly or indirectly to a first masking moiety (MM1) via a first cleavable moiety (CM1), wherein the LVD1 is covalently coupled directly or indirectly to a second masking moiety (MM2) via a second cleavable moiety (CM2), a second antigen binding domain (AB2) having specific binding affinity for a second antigen, wherein the AB2 comprises a heavy chain variable domain 2 (HVD2) and a light chain variable domain 2 (LVD2), a first dimerization domain (DD1) and a second dimerization domain (DD2).
2.20250345416PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODS
US - 13.11.2025
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No 18833073 Applicant BioNTech SE Inventor Ugur Sahin

The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

3.20250345284LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF
US - 13.11.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 18695471 Applicant The Trustees Of The University of Pennsylvania Inventor Michael Mitchell

The present disclosure relates, in part, to lipid nanoparticles (LNPs) comprising cholesterol substitutes (i.e., cholesterol analogs and/or derivatives) and methods of use thereof for in vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embodiments, the nucleic acid molecules encode chimeric antigen receptors (CARs). In certain embodiments, the target cell is a T cell. In certain embodiments, the LNPs of the present disclosure are anti-inflammatory. In certain embodiments, the present disclosure relates to the use of the LNPs described herein for the treatment, prevention, and/or amelioration of diseases and/or disorders in a subject, including but not limited to cancer.

4.WO/2025/228326RECOMBINANT RNA MOLECULE AND USE THEREOF
WO - 06.11.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/CN2025/091753 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided are a recombinant RNA molecule and a use thereof. The recombinant RNA molecule comprises a polynucleotide encoding a polypeptide of interest and 5'-UTR and/or 3'-UTR. The recombinant RNA molecule has improved translation efficiency and/or stability; and the expression level of the polypeptide and/or protein is increased. Also provided are a vector encoding the recombinant RNA molecule, a pharmaceutical composition comprising the recombinant RNA molecule, and a method for treating or preventing a disease by using the recombinant RNA molecule.
5.WO/2025/231360NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME
WO - 06.11.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/027494 Applicant MODERNATX, INC. Inventor AZMI, Ishara
The present disclosure provides novel CRISPR-associated (Cas) nucleases, as well as polynucleotides (e.g., DNA and RNA polynucleotides) encoding the same, host cells containing such nucleases and polynucleotides, and methods of using the foregoing compositions to effectuate genetic editing.
6.20250339533AGENTS AND METHODS FOR ACTIVATION AND TARGETING OF IMMUNE EFFECTOR CELLS
US - 06.11.2025
Int.Class A61K 40/31
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
40Cellular immunotherapy
30characterised by the recombinant expression of specific molecules in the cells of the immune system
31Chimeric antigen receptors
 Appl.No 18567478 Applicant BioNTech Cell & Gene Therapies GmbH Inventor Ugur SAHIN

The invention relates to agents and methods for activation of immune effector cells and targeted delivery of the activated immune effector cells to target cells. In one embodiment, the invention involves providing to a subject immune effector cells genetically modified to express a chimeric antigen receptor (CAR). In one embodiment, the invention involves administering RNA encoding a peptide or polypeptide (activation compound) comprising a binding moiety for the CAR and administering RNA encoding a peptide or polypeptide (docketing compound) comprising a binding moiety binding to target cells (primary targeting moiety) and a further binding moiety for the CAR (secondary target).

7.WO/2025/228409LIPID NANOPARTICLE AND USE THEREOF
WO - 06.11.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/CN2025/092313 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a lipid nanoparticle, which comprises an active component, an ionizable lipid, an auxiliary lipid, a structural lipid, and a polymer lipid. The polymer lipid accounts for 0-0.8 mol% of the total lipid existing in the lipid nanoparticle. The reduction in the content of the polymer lipid in the lipid nanoparticle can change the delivery specificity of the lipid nanoparticle, such that the lipid nanoparticle can target the spleen or immune cells.
8.WO/2025/223684METHODS AND COMPOSITIONS FOR STIMULATING IMMUNE RESPONSE
WO - 30.10.2025
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No PCT/EP2024/071234 Applicant BIONTECH SE Inventor SAHIN, Ugur
The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to compositions comprising an immunostimulatory RNA comprising sequences derived from an Influenza A virus nudeoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses, in particular as adjuvants for cancer vaccines.
9.20250332245IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA
US - 30.10.2025
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No 18946845 Applicant PFIZER INC. Inventor Pirada Suphaphiphat Allen

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

10.20250332244IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA
US - 30.10.2025
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No 18882451 Applicant Pfizer Inc. Inventor Bogos Agianian

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

# -